Symbols / KZIA $10.49 -5.50% Kazia Therapeutics Limited
KZIA Chart
About
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Fundamentals
Scroll to Statements| Market Cap | 119.87M | Enterprise Value | 59.39B | Income | -22.80M | Sales | 1.90M | Book/sh | 2.84 | Cash/sh | 0.01 |
| Dividend Yield | — | Payout | 0.00% | Employees | 6 | IPO | — | P/E | — | Forward P/E | -1037.18 |
| PEG | 1.01 | P/S | 63.13 | P/B | 3.70 | P/C | — | EV/EBITDA | -3328.80 | EV/Sales | 31279.33 |
| Quick Ratio | 2.86 | Current Ratio | 2.87 | Debt/Eq | 0.21 | LT Debt/Eq | — | EPS (ttm) | -7.62 | EPS next Y | -0.01 |
| EPS Growth | — | Revenue Growth | 3.12% | Earnings | — | ROA | -25.70% | ROE | -106.90% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -146.41% | Profit Margin | 0.00% | Shs Outstand | 11.43M | Shs Float | 3.91B | Short Float | 0.83% |
| Short Ratio | 0.73 | Short Interest | — | 52W High | 17.40 | 52W Low | 3.00 | Beta | 1.62 | Avg Volume | 200.26K |
| Volume | 262.81K | Target Price | $21.36 | Recom | Buy | Prev Close | $11.10 | Price | $10.49 | Change | -5.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.36
Mean price target
2. Current target
$10.49
Latest analyst target
3. DCF / Fair value
$1.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.49
Low
$18.48
High
$25.07
Mean
$21.36
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-15 | init | Laidlaw & Co. | — → Buy | $25 |
| 2026-01-28 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-12-12 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-10-02 | main | Maxim Group | Buy → Buy | $20 |
| 2025-07-10 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-06-11 | main | Maxim Group | Buy → Buy | $15 |
| 2025-02-06 | init | Maxim Group | — → Buy | $3 |
| 2024-07-12 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-04-11 | up | HC Wainwright & Co. | Neutral → Buy | $2 |
| 2022-08-02 | down | Maxim Group | Buy → Hold | — |
| 2022-08-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-10-14 | init | Maxim Group | — → Buy | $18 |
| 2021-01-05 | init | HC Wainwright & Co. | — → Buy | $17 |
- KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill Fri, 17 Apr 2026 07
- Cancer drug developer puts platform architect Sudha Rao in top science role - Stock Titan Wed, 15 Apr 2026 12
- The Technical Signals Behind (KZIA) That Institutions Follow - Stock Traders Daily Fri, 17 Apr 2026 12
- KZIA Initiated Coverage by Laidlaw & Co. -- Price Target Set at $25 - GuruFocus hu, 16 Apr 2026 07
- KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination - Stocktwits Wed, 19 Nov 2025 08
- Kazia adds AI-built cancer drug platform with lead candidate MSETC - Stock Titan Mon, 13 Apr 2026 21
- Dr. Sudha Rao joins Kazia Therapeutics (NASDAQ: KZIA) as part-time CSO - Stock Titan Wed, 15 Apr 2026 12
- Kazia Therapeutics (NASDAQ: KZIA) adds CSO; files supplement for 266,666 ADS - Stock Titan Wed, 15 Apr 2026 12
- Kazia Therapeutics (NASDAQ: KZIA) in-licenses SETDB1 platform, pays $1.39M - Stock Titan Mon, 13 Apr 2026 21
- Kazia Therapeutics (NASDAQ: KZIA) expects $46.5M net from PIPE to extend cash runway - Stock Titan ue, 02 Dec 2025 08
- Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan Wed, 01 Apr 2026 07
- Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan hu, 09 Apr 2026 07
- Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan ue, 31 Mar 2026 07
- [EFFECT] KAZIA THERAPEUTICS LTD SEC Filing - Stock Titan Mon, 30 Mar 2026 07
- Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan Mon, 13 Apr 2026 21
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.04
-98.18%
|
2.31
|
0.00
|
0.00
|
| Operating Revenue |
|
0.04
-98.18%
|
2.31
|
0.00
|
0.00
|
| Operating Expense |
|
14.26
-53.66%
|
30.77
+27.43%
|
24.15
-4.93%
|
25.40
|
| Research And Development |
|
7.33
-57.85%
|
17.38
+11.67%
|
15.56
-22.83%
|
20.17
|
| Selling General And Administration |
|
8.72
-35.71%
|
13.56
+58.02%
|
8.58
+63.80%
|
5.24
|
| Selling And Marketing Expense |
|
—
|
0.00
|
0.00
-100.00%
|
0.13
|
| General And Administrative Expense |
|
8.72
-35.71%
|
13.56
+58.02%
|
8.58
+67.87%
|
5.11
|
| Other Gand A |
|
8.72
-35.71%
|
13.56
+58.02%
|
8.58
+67.87%
|
5.11
|
| Other Operating Expenses |
|
-1.79
-932.95%
|
-0.17
-17200.00%
|
-0.00
+90.00%
|
-0.01
|
| Total Expenses |
|
14.26
-53.66%
|
30.77
+27.43%
|
24.15
-4.93%
|
25.40
|
| Operating Income |
|
-14.22
+50.05%
|
-28.46
-17.87%
|
-24.15
+4.93%
|
-25.40
|
| EBITDA |
|
-13.28
+50.05%
|
-26.59
-19.37%
|
-22.28
+5.33%
|
-23.53
|
| Normalized EBITDA |
|
-7.46
+72.08%
|
-26.71
-4.08%
|
-25.66
-9.00%
|
-23.55
|
| Reconciled Depreciation |
|
0.93
-50.03%
|
1.87
+0.00%
|
1.87
+0.00%
|
1.87
|
| EBIT |
|
-14.22
+50.05%
|
-28.46
-17.87%
|
-24.15
+4.93%
|
-25.40
|
| Total Unusual Items |
|
-5.83
-4994.96%
|
0.12
-96.49%
|
3.39
+22486.67%
|
0.01
|
| Total Unusual Items Excluding Goodwill |
|
-5.83
-4994.96%
|
0.12
-96.49%
|
3.39
+22486.67%
|
0.01
|
| Special Income Charges |
|
-5.83
-4994.96%
|
0.12
-96.49%
|
3.39
+22486.67%
|
0.01
|
| Impairment Of Capital Assets |
|
13.38
|
0.00
|
0.00
|
—
|
| Restructuring And Mergern Acquisition |
|
-7.55
-6247.90%
|
-0.12
+96.49%
|
-3.39
|
0.00
|
| Write Off |
|
—
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Net Income |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Pretax Income |
|
-22.45
+17.01%
|
-27.05
-30.44%
|
-20.74
+18.30%
|
-25.38
|
| Net Non Operating Interest Income Expense |
|
0.07
+500.00%
|
0.01
-45.45%
|
0.02
+1000.00%
|
0.00
|
| Net Interest Income |
|
0.07
+500.00%
|
0.01
-45.45%
|
0.02
+1000.00%
|
0.00
|
| Interest Income Non Operating |
|
0.07
+500.00%
|
0.01
-45.45%
|
0.02
+1000.00%
|
0.00
|
| Interest Income |
|
0.07
+500.00%
|
0.01
-45.45%
|
0.02
+1000.00%
|
0.00
|
| Other Income Expense |
|
-8.30
-692.65%
|
1.40
-58.65%
|
3.39
+22486.67%
|
0.01
|
| Other Non Operating Income Expenses |
|
-2.48
-293.29%
|
1.28
+128100.00%
|
0.00
|
—
|
| Tax Provision |
|
-1.75
-544.28%
|
-0.27
+0.00%
|
-0.27
+26.36%
|
-0.37
|
| Tax Rate For Calcs |
|
0.00
+676.32%
|
0.00
-23.34%
|
0.00
-9.86%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.45
-38101.21%
|
0.00
-97.31%
|
0.04
+20259.85%
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Net Income From Continuing Operation Net Minority Interest |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Net Income From Continuing And Discontinued Operation |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Net Income Continuous Operations |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Normalized Income |
|
-15.33
+43.00%
|
-26.90
-12.97%
|
-23.81
+4.87%
|
-25.03
|
| Net Income Common Stockholders |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Diluted EPS |
|
-18.90
|
—
|
-56.15
+39.66%
|
-93.05
|
| Basic EPS |
|
-18.90
|
—
|
-11.25
+40.41%
|
-18.88
|
| Basic Average Shares |
|
1.10
|
—
|
1.84
+39.12%
|
1.32
|
| Diluted Average Shares |
|
1.10
|
—
|
1.84
+39.12%
|
1.32
|
| Diluted NI Availto Com Stockholders |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Other Taxes |
|
—
|
—
|
0.00
|
0.00
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets |
|
6.06
-71.92%
|
21.59
-23.14%
|
28.08
-21.75%
|
35.89
|
| Current Assets |
|
4.93
-19.71%
|
6.14
-42.95%
|
10.77
+14.00%
|
9.45
|
| Cash Cash Equivalents And Short Term Investments |
|
4.34
+162.22%
|
1.66
-68.38%
|
5.24
-28.80%
|
7.36
|
| Cash And Cash Equivalents |
|
4.34
+162.22%
|
1.66
-68.38%
|
5.24
-28.80%
|
7.36
|
| Cash Equivalents |
|
—
|
—
|
—
|
0.00
|
| Cash Financial |
|
4.34
+162.22%
|
1.66
-68.38%
|
5.24
-28.80%
|
7.36
|
| Receivables |
|
0.09
-32.33%
|
0.13
+26.67%
|
0.10
+105.88%
|
0.05
|
| Accounts Receivable |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Other Receivables |
|
0.09
-32.33%
|
0.13
+27.88%
|
0.10
+103.92%
|
0.05
|
| Taxes Receivable |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
0.50
-88.54%
|
4.36
-19.74%
|
5.43
+166.37%
|
2.04
|
| Other Current Assets |
|
—
|
—
|
—
|
—
|
| Total Non Current Assets |
|
1.13
-92.70%
|
15.44
-10.81%
|
17.31
-34.52%
|
26.44
|
| Goodwill And Other Intangible Assets |
|
1.09
-92.94%
|
15.40
-10.82%
|
17.27
-9.77%
|
19.14
|
| Other Intangible Assets |
|
1.09
-92.94%
|
15.40
-10.82%
|
17.27
-9.77%
|
19.14
|
| Non Current Prepaid Assets |
|
0.04
+0.00%
|
0.04
-6.98%
|
0.04
-99.41%
|
7.30
|
| Total Liabilities Net Minority Interest |
|
14.36
-54.55%
|
31.60
+97.09%
|
16.03
-8.97%
|
17.61
|
| Current Liabilities |
|
14.05
-45.52%
|
25.80
+241.00%
|
7.57
+12.44%
|
6.73
|
| Payables And Accrued Expenses |
|
10.12
-32.85%
|
15.07
+248.05%
|
4.33
+15.16%
|
3.76
|
| Payables |
|
5.64
+24.12%
|
4.55
+430.69%
|
0.86
-43.77%
|
1.52
|
| Accounts Payable |
|
5.64
+24.12%
|
4.55
+430.69%
|
0.86
-43.77%
|
1.52
|
| Other Payable |
|
—
|
—
|
—
|
2.24
|
| Current Accrued Expenses |
|
4.47
-57.49%
|
10.52
+202.97%
|
3.47
+55.35%
|
2.23
|
| Employee Benefits |
|
0.04
+5.71%
|
0.04
-40.68%
|
0.06
-49.57%
|
0.12
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.39
+6.85%
|
0.36
-47.10%
|
0.69
+86.99%
|
0.37
|
| Current Debt And Capital Lease Obligation |
|
0.40
-37.54%
|
0.63
-64.70%
|
1.80
-2.44%
|
1.84
|
| Current Debt |
|
0.40
-37.54%
|
0.63
-64.70%
|
1.80
-2.44%
|
1.84
|
| Other Current Borrowings |
|
0.40
-37.54%
|
0.63
-64.70%
|
1.80
|
—
|
| Other Current Liabilities |
|
3.15
-67.63%
|
9.73
+1197.47%
|
0.75
-1.19%
|
0.76
|
| Total Non Current Liabilities Net Minority Interest |
|
0.31
-94.68%
|
5.80
-31.46%
|
8.47
-22.20%
|
10.89
|
| Non Current Deferred Liabilities |
|
0.27
-86.52%
|
2.02
-11.84%
|
2.29
-10.59%
|
2.56
|
| Non Current Deferred Taxes Liabilities |
|
0.27
-86.52%
|
2.02
-11.84%
|
2.29
-10.59%
|
2.56
|
| Other Non Current Liabilities |
|
—
|
3.75
-38.70%
|
6.12
-25.44%
|
8.21
|
| Stockholders Equity |
|
-8.30
+17.13%
|
-10.02
-183.13%
|
12.05
-34.06%
|
18.27
|
| Common Stock Equity |
|
-8.30
+17.13%
|
-10.02
-183.13%
|
12.05
-34.06%
|
18.27
|
| Capital Stock |
|
123.05
+21.06%
|
101.64
+4.30%
|
97.45
+15.36%
|
84.48
|
| Common Stock |
|
123.05
+21.06%
|
101.64
+4.30%
|
97.45
+15.36%
|
84.48
|
| Share Issued |
|
809.42
+143.18%
|
332.85
+45.97%
|
228.03
+64.34%
|
138.76
|
| Ordinary Shares Number |
|
809.42
+143.18%
|
332.85
+45.97%
|
228.03
+64.34%
|
138.76
|
| Additional Paid In Capital |
|
0.38
|
0.00
|
0.00
|
0.00
|
| Retained Earnings |
|
-134.83
-17.11%
|
-115.13
-29.24%
|
-89.08
-29.83%
|
-68.62
|
| Gains Losses Not Affecting Retained Earnings |
|
3.10
-10.79%
|
3.48
-5.60%
|
3.68
+52.61%
|
2.41
|
| Total Equity Gross Minority Interest |
|
-8.30
+17.13%
|
-10.02
-183.13%
|
12.05
-34.06%
|
18.27
|
| Total Capitalization |
|
-8.30
+17.13%
|
-10.02
-183.13%
|
12.05
-34.06%
|
18.27
|
| Working Capital |
|
-9.12
+53.60%
|
-19.65
-712.78%
|
3.21
+17.86%
|
2.72
|
| Invested Capital |
|
-7.91
+15.75%
|
-9.38
-167.77%
|
13.85
-31.17%
|
20.12
|
| Total Debt |
|
0.40
-37.54%
|
0.63
-64.70%
|
1.80
-2.44%
|
1.84
|
| Net Tangible Assets |
|
-9.39
+63.06%
|
-25.42
-387.01%
|
-5.22
-504.05%
|
-0.86
|
| Tangible Book Value |
|
-9.39
+63.06%
|
-25.42
-387.01%
|
-5.22
-504.05%
|
-0.86
|
| Other Equity Interest |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.28
-38.59%
|
-9.58
+36.78%
|
-15.16
+33.42%
|
-22.76
|
| Cash Flow From Continuing Operating Activities |
|
-13.28
-38.59%
|
-9.58
+36.78%
|
-15.16
+33.42%
|
-22.76
|
| Net Income From Continuing Operations |
|
-20.70
+22.69%
|
-26.78
-30.85%
|
-20.46
+18.19%
|
-25.01
|
| Depreciation Amortization Depletion |
|
0.93
-50.03%
|
1.87
+0.00%
|
1.87
+0.00%
|
1.87
|
| Amortization Cash Flow |
|
0.93
-50.03%
|
1.87
+0.00%
|
1.87
+0.00%
|
1.87
|
| Depreciation And Amortization |
|
0.93
-50.03%
|
1.87
+0.00%
|
1.87
+0.00%
|
1.87
|
| Amortization Of Intangibles |
|
0.93
-50.03%
|
1.87
+0.00%
|
1.87
+0.00%
|
1.87
|
| Other Non Cash Items |
|
-5.83
-195.59%
|
6.09
+390.65%
|
-2.10
-1479.61%
|
0.15
|
| Stock Based Compensation |
|
0.65
+22.51%
|
0.53
-54.01%
|
1.16
-30.81%
|
1.68
|
| Asset Impairment Charge |
|
13.38
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
0.31
+1650.00%
|
-0.02
-143.48%
|
0.05
+102.14%
|
-2.15
|
| Unrealized Gain Loss On Investment Securities |
|
0.98
+176.60%
|
-1.28
|
0.00
|
0.00
|
| Net Foreign Currency Exchange Gain Loss |
|
0.31
+1650.00%
|
-0.02
-143.48%
|
0.05
+102.14%
|
-2.15
|
| Change In Working Capital |
|
-3.01
-130.07%
|
10.00
+130.89%
|
4.33
+402.55%
|
0.86
|
| Change In Receivables |
|
3.80
+75880.00%
|
0.01
-99.86%
|
3.45
+49385.71%
|
-0.01
|
| Changes In Account Receivables |
|
3.80
+75880.00%
|
0.01
-99.86%
|
3.45
+57600.00%
|
-0.01
|
| Change In Prepaid Assets |
|
—
|
—
|
0.36
-76.66%
|
1.56
|
| Change In Payables And Accrued Expense |
|
-4.95
-146.10%
|
10.74
+1787.17%
|
0.57
+207.77%
|
-0.53
|
| Change In Payable |
|
-4.95
-146.10%
|
10.74
+1787.17%
|
0.57
+207.77%
|
-0.53
|
| Change In Other Working Capital |
|
-1.72
-177.26%
|
-0.62
-8757.14%
|
-0.01
+95.81%
|
-0.17
|
| Change In Other Current Assets |
|
0.10
-90.39%
|
1.04
+185.21%
|
0.36
+231.77%
|
-0.28
|
| Change In Other Current Liabilities |
|
-0.24
+79.52%
|
-1.16
-2482.22%
|
-0.04
-102.44%
|
1.84
|
| Investing Cash Flow |
|
—
|
0.00
|
0.00
+100.00%
|
-2.37
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
|
0.00
+100.00%
|
-2.37
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
—
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
-2.37
|
| Purchase Of Business |
|
—
|
—
|
—
|
-2.37
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-2.37
|
| Financing Cash Flow |
|
15.98
+167.03%
|
5.99
-53.86%
|
12.97
+248.15%
|
3.73
|
| Cash Flow From Continuing Financing Activities |
|
15.98
+167.03%
|
5.99
-53.86%
|
12.97
+248.15%
|
3.73
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
0.41
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.78
|
0.00
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.37
|
0.00
|
0.00
|
| Short Term Debt Issuance |
|
0.00
-100.00%
|
0.78
|
0.00
|
0.00
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.37
|
0.00
|
0.00
|
| Net Short Term Debt Issuance |
|
0.00
-100.00%
|
0.41
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
14.80
+165.30%
|
5.58
-56.98%
|
12.97
+248.15%
|
3.73
|
| Proceeds From Stock Option Exercised |
|
1.18
|
0.00
|
0.00
|
—
|
| Changes In Cash |
|
2.70
+175.19%
|
-3.60
-64.65%
|
-2.18
+89.79%
|
-21.40
|
| Effect Of Exchange Rate Changes |
|
-0.02
-233.33%
|
0.01
-81.25%
|
0.06
-94.55%
|
1.18
|
| Beginning Cash Position |
|
1.66
-68.38%
|
5.24
-28.80%
|
7.36
-73.32%
|
27.59
|
| End Cash Position |
|
4.34
+162.22%
|
1.66
-68.38%
|
5.24
-28.80%
|
7.36
|
| Free Cash Flow |
|
-13.28
-38.59%
|
-9.58
+36.78%
|
-15.16
+33.42%
|
-22.76
|
| Common Stock Issuance |
|
14.80
+165.30%
|
5.58
-56.98%
|
12.97
+248.15%
|
3.73
|
| Issuance Of Capital Stock |
|
14.80
+165.30%
|
5.58
-56.98%
|
12.97
+248.15%
|
3.73
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42013-11-06 View
- 42013-10-29 View
- 42013-10-17 View
- 42013-02-27 View
- 42012-12-05 View
- 42012-11-21 View
- 42012-05-15 View
- 42011-12-30 View
- 42011-10-05 View
- 42011-05-10 View
- 42008-07-31 View
- 42008-07-30 View
- 42008-03-27 View
- 42007-09-11 View
- 42007-07-12 View
- 42007-07-02 View
- 42007-06-26 View
- 42007-06-22 View
- 42007-06-20 View
- 42007-06-18 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|